Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Trial records for Larazotide acetate

8 records for Larazotide acetate, of which 2 are published trials.

Showing 0 records on this page

Records

8 documents

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
CELIAC-PH3-CEDLARALarazotide acetatePhase 3TerminatedRandomised, double-blind, placebo-controlled2022Not rated
CELIAC-PH3-CEDLARA-BODY-COMPprogramme recordLarazotide acetatePhase 3ReportedRandomised, double-blind, placebo-controlled2022Very low
CELIAC-PH3-CEDLARA-REGIONAL-JPprogramme recordLarazotide acetatePhase 3ReportedRandomised, double-blind, placebo-controlled2022Very low
CELIAC-PH2BLarazotide acetatePhase 2bReportedRandomised, double-blind, placebo-controlled3422015Moderate
CELIAC-PH2B-PKprogramme recordLarazotide acetatePhase 1ReportedPhase 1 ascending dose2015Very low
CELIAC-PH2B-RENAL-IMPprogramme recordLarazotide acetatePhase 1ReportedPhase 1 ascending dose2015Very low
CELIAC-PH2B-HEPATIC-IMPprogramme recordLarazotide acetatePhase 1ReportedPhase 1 ascending dose2015Very low
CELIAC-PH2B-DDIprogramme recordLarazotide acetatePhase 1ReportedRandomised crossover2015Very low
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.